FOXO4-DRI quick reference
What is FOXO4-DRI?
Lab-designed peptide that makes aged ('senescent') cells self-destruct.
People try short pulses hoping to clear aged cells.
Cell and mouse data only; no human study.
How FOXO4-DRI works
Frees p53 inside senescent cells.
p53 leaves the nucleus and triggers apoptosis.
Resists breakdown by enzymes.
Selectivity differs by cell type and tissue.
What FOXO4-DRI is studied for
Restored fitness, fur density and kidney function (2017).
Reduced doxorubicin toxicity in mice.
Aged mice made more testosterone after treatment (2020).
Cut scarring in bleomycin mice (2022).
Cleared senescent chondrocytes and keloid fibroblasts in dishes.
Worsened pulmonary hypertension in one mouse model (2023).
FOXO4-DRI dosing protocol
| Item | Finding |
|---|---|
| Human dose | Not established |
| Studied in | Mice (injection into the belly cavity) and cell cultures |
| Mouse schedule (aged mice 2020; lung fibrosis mice 2022) | 5 mg per kg, every other day, 3 doses |
Sources: Aging 2020 (PMID 31959736) and J Cell Mol Med 2022 (PMID 35510614), whose full texts give the 5 mg per kg dose. Mouse doses do not convert directly to people.
Label and trial amounts come from the sources below. Community amounts are what people report; they have not been tested.
Mixing
Example only. Community vial sizes vary.
What the research found
There are no human results, so these are the evidence facts, all from mice and cells:
Baar MP et al. Cell 2017 (PMID 28340339): in aged and fast-aging mice, restored fitness, fur density and kidney function. Aging 2020 (PMID 31959736) and J Cell Mol Med 2022 (PMID 35510614) are later mouse studies.
FOXO4-DRI community experience
What users report. Not tested in trials.
Positive reports
- Energy A few feel better after a cycle.
- Recovery Rare reports of quicker recovery.
- Less inflammation Reports are inconsistent and overlap other changes.
Negative & mixed
- Site burning Burning, itching or swelling is common.
- No effect Many feel nothing.
- Flu-like days Fatigue, headache or flu feelings are scattered.
FOXO4-DRI stacking
Proposed 'clear then rebuild' idea. No human study.
Cell clearing plus mitochondria support. Not studied together.
Fisetin, quercetin or dasatinib make effects hard to predict.
FOXO4-DRI side effects & safety
Common
- No human data, so rates are unknown.
- Burning, itching or swelling at the site (community).
- Fatigue, headache, flu-like feeling (community).
- 2017 paper: well tolerated in mice.
Less common
- Mouse study: clearing senescent lung vessel cells worsened pulmonary hypertension.
- Off-target cell death in healthy tissue is untested.
- Immune reactions to the peptide are untested.
Precautions
- No human dose, safety program or approved use.
- Cancer or chemo: effects on tumors are untested in people.
- Lung or vessel disease: senolysis worsened hypertension in mice.
- No reproductive safety data.
Our verdict on FOXO4-DRI
Striking mouse work, but selectivity and safety in people are unknown. Community doses have no source.
FOXO4-DRI FAQ
Is FOXO4-DRI a senolytic?
Yes. It is designed to kill senescent cells through p53.
Has it been tested in people?
No. Only cells and mice.
What do mouse studies use?
5 mg/kg every other day for 3 doses. It does not scale to people.
Does it raise testosterone?
In aged mice, yes (2020). Not shown in people.
Sources
- Baar MP et al. Cell 2017, PMID 28340339
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency, Aging 2020, PMID 31959736
- FOXO4 peptide in bleomycin-induced pulmonary fibrosis in mice, J Cell Mol Med 2022, PMID 35510614
- Targeting senescence-like fibroblasts radiosensitizes NSCLC, JCI Insight 2021, PMID 34877934
- Eliminating senescent cells can promote pulmonary hypertension, Circulation 2023, PMID 36515093
- Senolytic peptide FOXO4-DRI removes senescent cells from expanded human chondrocytes, Front Bioeng Biotechnol 2021, PMID 33996787
- FOXO4-DRI induces keloid senescent fibroblast apoptosis, Commun Biol 2025, PMID 39994346